Reversión de anticoagulantes orales directos: una perspectiva desde urgencias

Vista sencilla de ítem
dc.contributor.authorZuluaga Gómez, Mateo
dc.contributor.authorZuluaga Arbeláez, Nicolás
dc.contributor.authorBerrouet Mejía, Marie Claire
dc.contributor.authorEstrada Atehortúa, Andrés Felipe
dc.date.accessioned2024-07-23T20:30:40Z
dc.date.available2024-07-23T20:30:40Z
dc.date.issued2020-07-08
dc.description.abstractEl sangrado en contexto de anticoagulación es uno de los riesgos que tienen ciertos pacientes durante determinados tratamientos, y es potencialmente mortal. Es importante conocer la farmacocinética de estas moléculas para predecir cuál será su comportamiento. Además se requiere juicio clínico en todos los casos de sangrado para determinar el manejo de acuerdo a la severidad. El objetivo de esta revisión es presentar un enfoque del paciente anticoagulado con sangrado en el servicio de urgencias. Temas tratados. Farmacocinética y farmacodinámica, generalidades, sangrado mayor y no mayor, opciones de reversión y tratamiento. Conclusión. En presencia de anticoagulantes orales directos (DOACS) se debe evaluar la gravedad del sangrado y el grado de anticoagulación, pues las estrategias de manejo se orientan dependiendo de si se trata de un sangrado mayor o menor.spa
dc.description.abstractenglishBleeding in the context of anticoagulation is one of the risks faced by some patients during certain treatments, and is potentially deadly. It is important to be aware of the pharmacokinetics of these molecules in order to predict their behavior. Clinical judgment is also required in all cases of bleeding, because management will depend on its severity. The purpose of this review is to present an approach to an anticoagulated patient with bleeding in the emergency ward. Topics Discussed. Pharmacokinetics and pharmacodynamics, generalities, major and non- major bleeding, reversal options and treatment. Conclusion. If direct oral anticoagulants (DOACS) are present, it is necessary to assess the severity of bleeding and the degree of anticoagulation, because the management treatment depends on whether bleeding is major or minor.eng
dc.description.abstractotherO sangramento no contexto da anticoagulação é um dos riscos que alguns pacientes apresentam durante certos tratamentos e é potencialmente fatal. É importante conhecer a farmacocinética dessas moléculas para prever qual será o seu comportamento. Além disso, o julgamento clínico é necessário em todos os casos de sangramento para determinar o manejo de acordo com a gravidade. O objetivo desta revisão é apresentar uma abordagem do paciente anticoagulado com sangramento no departamento de emergência. Tópicos abordados. Farmacocinética e farmacodinâmica, visão geral, sangramento maior e não maior, opções de reversão e tratamento. Conclusão. Na presença de anticoagulantes orais diretos (DOACS), a gravidade do sangramento e o grau de anticoagulação devem ser avaliados, uma vez que são orientadas as estratégias de manejo de acordo com o sangramento, se for maior ou menorpor
dc.format.mimetypeapplication/pdfspa
dc.identifier.doihttps://doi.org/10.29375/01237047.3841
dc.identifier.instnameinstname:Universidad Autónoma de Bucaramanga UNABspa
dc.identifier.issni-ISSN 0123-7047spa
dc.identifier.issne-ISSN 2382-4603
dc.identifier.reponamereponame:Repositorio Institucional UNABspa
dc.identifier.repourlrepourl:https://repository.unab.edu.cospa
dc.identifier.urihttp://hdl.handle.net/20.500.12749/25681
dc.language.isospaspa
dc.publisher.facultyFacultad Ciencias de la Saludspa
dc.publisher.grantorUniversidad Autónoma de Bucaramanga UNABspa
dc.relationhttps://revistas.unab.edu.co/index.php/medunab/article/view/3841/3358spa
dc.relation.referencesChen A, Stecker E, A Warden B. Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges. JAm Heart Assoc [Internet]. 2020 Jun 15 [citado 2020 Jun 27];e017559. Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/32538234
dc.relation.referencesHo KH, Van Hove M, Leng G. Trends in anticoagulant prescribing: A review of local policies in English primary care [Internet]. Vol. 20, BMC Health Services Research. BioMed Central Ltd.; 2020 [citado 2020 Jun 27]. p. 279. https://doi.org/10.1186/s12913-020- 5058-1
dc.relation.referencesRuff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: A meta-analysis of randomised trials. Lancet [Internet]. 2014 [citado 2020 Jun 27];383(9921):955-62. https:// doi.org/10.1016/S0140-6736(13)62343-0
dc.relation.referencesProvidência R, Grove EL, Husted S, Barra S, Boveda S, Morais J. A meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: Comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens. Thromb Res [Internet]. 2014 Dec 1 [citado 2020 Jun 28];134(6):1253-64. https://doi. org/10.1016/j.thromres.2014.10.002
dc.relation.referencesBlech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos [Internet]. 2008 Feb [citado 2020 Jun 28];36(2):386-99. https://doi.org/10.1124/ dmd.107.019083
dc.relation.referencesStangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate [Internet]. Vol. 47, Clinical Pharmacokinetics. Clin Pharmacokinet; 2008 [citado 2020 Jun 28]. p. 285-95. https://doi. org/10.2165/00003088-200847050-00001
dc.relation.referencesEriksson BI, Quinlan DJ, Weitz JI. Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development [Internet]. Vol. 48, Clinical Pharmacokinetics. Clin Pharmacokinet; 2009 [citado 2020 Jun 28]. p. 1-22. https://doi.org/10.2165/0003088-200948010-00001
dc.relation.referencesCui Y, Song Y, Wang J, Yu Z, Schuster A, Barrett YC, et al. Single- and multiple-dose pharmacokinetics, pharmacodynamics, and safety of apixaban in healthy Chinese subjects. Clin Pharmacol Adv Appl [Internet]. 2013 Dec 6 [citado 2020 Jun 28];5:177-84. Disponible en: /pmc/articles/PMC3861362/?report=abstract
dc.relation.referencesHe K, Luettgen JM, Zhang D, He B, Grace JE, Xin B, et al. Preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. Eur J Drug Metab Pharmacokinet [Internet]. 2011 Sep [citado 2020 Jun 28];36(3):129- 39. https://doi.org/10.1007/s13318-011-0037-x
dc.relation.referencesTamargo J. Edoxabán. Propiedades farmacocinéticas y farmacodinámicas. Rev Esp Cardiol Supl [Internet]. 2016 Jan 1 [citado 2020 Jun 26];16:60-6. https://doi. org/10.1016/S1131-3587(16)30017-6
dc.relation.referencesTomaselli GF, Mahaffey KW, Cuker A, Dobesh PP, Doherty JU, Eikelboom JW, et al. 2017 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Oral Anticoagulants: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol [Internet]. 2017 Dec 19 [citado 2020 Jun 28];70(24):3042-67. https://doi.org/10.1016/j. jacc.2017.09.1085
dc.relation.referencesSchulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients [Internet]. Vol. 3, Journal of Thrombosis and Haemostasis. J Thromb Haemost; 2005 [citado 2020 Jun 27]. p. 692-4. https:// doi.org/10.1111/j.1538-7836.2005.01204.x
dc.relation.referencesSamuelson BT, Cuker A, Siegal DM, Crowther M, Garcia DA. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants: A Systematic Review. Chest [Internet]. 2017 Jan 1 [citado 2020 Jun 27];151(1):127-38. https://doi. org/10.1016/j.chest.2016.08.1462
dc.relation.referencesShih AW, Crowther MA. Reversal of direct oral anticoagulants: A practical approach. Hematology [Internet]. 2016 [citado 2020 Jun 28];2016(1):612-9. https://doi.org/10.1182/asheducation-2016.1.612
dc.relation.referencesSyed YY. Idarucizumab: A review as a reversal agent for dabigatran [Internet]. Vol. 16, American Journal of Cardiovascular Drugs. Springer International Publishing; 2016 [citado 2020 Jun 28]. p. 297-304. https://doi.org/10.1007/s40256-016-0181-4
dc.relation.referencesPollack C V., Reilly PA, Eikelboom J, Glund S, Verhamme P, Bernstein RA, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med [Internet]. 2015 Aug 6 [citado 2020 Jun 28];373(6):511-20. https://doi. org/10.1056/NEJMoa1502000
dc.relation.referencesKhadzhynov D, Wagner F, Formella S, Wiegert E, Moschetti V, Slowinski T, et al. Effective elimination of dabigatran by haemodialysis: A phase I single- centre study in patients with end-stage renal disease. Thromb Haemost [Internet]. 2013 Feb 7 [citado 2020 Jun 28];109(4):596-605. https://doi.org/10.1160/ TH12-08-0573
dc.relation.referencesSiegal DM. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents. J Thromb Thrombolysis [Internet]. 2015 [citado 2020 Jun 28];39(3):395-402. https://doi.org/10.1007/s11239- 015-1167-9
dc.relation.referencesCrowther M, Crowther MA. Antidotes for novel oral anticoagulants: Current status and future potential. Arterioscler Thromb Vasc Biol [Internet]. 2015 agosto 25 [citado 2020 Jun 28];35(8):1736-45. https://doi. org/10.1161/ATVBAHA.114.303402
dc.relation.referencesEerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: A randomized, placebo-controlled, crossover study in healthy subjects. Circulation [Internet]. 2011 Oct 4 [citado 2020 Jun 28];124(14):1573-9. https://doi. org/10.1161/CIRCULATIONAHA.111.029017
dc.relation.referencesM L, KT M, CF C, D K, SD B, SZ G, et al. Comparison of Three-Factor and Four-Factor Prothrombin Complex Concentrates Regarding Reversal of the Anticoagulant Effects of Rivaroxaban in Healthy Volunteers. J Thromb Haemost [Internet]. 2014 [citado 2020 Jun 28];12(9). https://doi.org/10.1111/jth.12599
dc.relation.referencesZahir H, Brown KS, Vandell AG, Desai M, Maa JF, Dishy V, et al. Edoxaban effects on bleeding following punch biopsy and reversal by a 4-factor prothrombin complex concentrate. Circulation [Internet]. 2015 [citado 2020 Jun 28];131(1):82-90. https://doi. org/10.1161/CIRCULATIONAHA.114.013445
dc.relation.urihttps://revistas.unab.edu.co/index.php/medunab/issue/view/264spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.creativecommonsAtribución-NoComercial-SinDerivadas 2.5 Colombia*
dc.rights.localAbierto (Texto Completo)spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.sourceVol. 23 Núm. 3 (2020): diciembre 2020 - marzo 2021: Depresión, Infecciones Urinarias, Agotamiento Profesional; 483-490spa
dc.subjectAnticoagulantes directosspa
dc.subjectSangradospa
dc.subjectIdarucizumabspa
dc.subjectAndexanetspa
dc.subjectMedicamentos hemoderivadosspa
dc.subject.keywordsMedical scienceseng
dc.subject.keywordsLife scienceseng
dc.subject.keywordsDirect anticoagulantseng
dc.subject.keywordsBleedingeng
dc.subject.keywordsIdarucizumabeng
dc.subject.keywordsAndexaneteng
dc.subject.keywordsBlood-derivative drugseng
dc.subject.keywordsAnticoagulantes diretospor
dc.subject.keywordsSangramentopor
dc.subject.keywordsIdarucizumabepor
dc.subject.keywordsAndexanetpor
dc.subject.keywordsMedical scienceseng
dc.subject.keywordsLife scienceseng
dc.subject.keywordsHealth scienceseng
dc.subject.keywordsCiências médicaspor
dc.subject.keywordsCiências da vidapor
dc.subject.keywordsCiências da saúdepor
dc.subject.lembCiencias médicasspa
dc.subject.lembCiencias de la vidaspa
dc.subject.proposalCiencias de la saludspa
dc.titleReversión de anticoagulantes orales directos: una perspectiva desde urgenciasspa
dc.title.translatedReversion of direct oral anticoagulants: an outlook from the emergency wardeng
dc.title.translatedReversão de anticoagulantes orais diretos: Uma perspectiva da emergênciapor
dc.typeArticleeng
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.driverinfo:eu-repo/semantics/article
dc.type.hasversioninfo:eu-repo/semantics/publishedVersion
dc.type.localArtículospa
dc.type.redcolhttp://purl.org/redcol/resource_type/ART

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
Artículo.pdf
Tamaño:
602.45 KB
Formato:
Adobe Portable Document Format
Descripción:
Artículo
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
183 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Revista MedUNAB